Open Nav

Berlin Cures Holding AG

  • Johannes Mueller, Berlin Cures

Raise awareness in investor/partner community

  • Date:Wednesday, October 17
  • Time:2:00 PM - 2:15 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Berlin Cures is rapidly emerging as the only company with an effective and practical treatment for removing autoantibodies that cause disease in about 80 percent of heart failure patients with DCM. As we have completed a Phase 1b study and prepare to launch a Phase 2 study in 2018 on a DNA aptamer-based compound known as BC 007, we have already demonstrated that our approach has unique benefits for heart failure treatment. Our technology platform is also the foundation for developing drugs that hold promise for treating other diseases associated with autoantibodies, such as pulmonary hypertension, glaucoma, and preeclampsia.
  • Company
  • Company HQ City:Zug
  • Company HQ Country:Switzerland
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development :BC 007
  • Development Phase of Primary Product:Phase II
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :1
  • Total Amount Raised to Date, In All Rounds:10 million
Johannes Mueller
Berlin Cures